1. Genotoxic and carcinogenic impurities in drug substances and products: recommended approaches. U.S. Department of Health and Human Services, Food. and Drug Administration, Center for Drug Evaluation and Research (CDER), Silver Spring, MD, USA, December 2008.
2. Guideline on the Limits of Genotoxic Impurities, Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency (EMEA), London, 28 June, 2006 (CPMP/SWP/5199/02, EMEA/CHMP/QWP/251344/2006).
3. International Conference on Harmonisation (ICH), Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk, Guideline M7, 2013, Geneva, Switzerland.
4. A core in vitro genotoxicity battery comprising the Ames test plus the in vitro micronucleus test is sufficient to detect rodent carcinogens and in vivo genotoxins;Kirkland;Mutat.,2011
5. Mechanism and processing parameters affecting the formation of methyl methanesulfonate from methanol and methanesulfonic acid: an illustrative example for sulfonate ester impurity formation;Teasdale;Org. Process Res. Dev.,2009